Thus mutation at both BRAF and CRAF have been detected in certain cancer patients and other studies have shown that the levels of mutant and WT B-Raf, Raf-1 and RKIP will influence the levels of transformation observed, hence there is a strong basis for the development of Raf inhibitors [3]. This evidence concerns the gene BRAF and cancer.